Our specialist medical device team work with diverse global companies within the industry to sustain growth, exploit current and future innovations, and secure their business's success. Our clients are multinational corporations and start-ups within the medical devices industry from companies within medical devices or in vitro diagnostic medical devices.
With sector-specific expertise grounded in scientific intelligence and technological know-how, clients value our knowledge of the regulatory frameworks shaping clients' strategic options, the technology being deployed, and our ability to execute complex legal solutions across multi-jurisdictions.
We ensure that our clients operate within the boundaries of medical regulations, data privacy, competition/anti-trust, procurement, pricing and reimbursement, advertising and promotion, and anti-bribery compliance/fraud and abuse laws.
We are pivotal in leveraging growth through strategic alliances, fundraisings, IP and compliant data privacy and security activities, and are relied on to resolve both offensive and defensive cross-jurisdiction patent litigation.
With in-depth sector expertise, we also actively engage with the wider medical devices industry through our connections with esteemed industry bodies and as leading voices in industry publications and wider expert webinar/seminar series.
Eckert & Ziegler Strahlen- und Medizintechnik AG, a German FSE stock listed company on all aspects of a cross-border merger. Eckert & Ziegler Strahlen- und Medizintechnik AG, one of the world's largest suppliers of isotope technology components for radiation therapy and nuclear medicine with headquarters in Berlin, as absorbing entity merged with the Belgian Eckert & Ziegler BEBIG SA, which was listed on the Euronext Brussels stock exchange. The transaction is a rare example of cross-border mergers of two listed companies on the basis of the European harmonized requirements of the EU Company Directive (EU) 2017/1132.
Press releaseHalyard Health on the sale of its surgical and infection prevention (S&IP) business to OMI.
Actualités et publications récentes
Purpose limitation and data minimisation: key considerations for AI training in the life sciences sector
The use of real-world evidence data to train AI models is becoming a critical component in advancing research and drug development. We explore how two of the GDPR's guiding principles are more than just regulatory requirements.
par Victoria Hordern et Dr. Tim Schwarz
3 de 10 Publications
The UPC: a new rocket docket for life sciences patent litigation
Orphan drug protection: clarification needed
par Dr Paul England
Updated post-market surveillance (PMS) rules for medical devices in the UK: differences from the EU regulations
par Alison Dennis et Alice Matthews
Life sciences M&A roundup: October 2024
par Ross McNaughton et Sarah Cole
Événements connexes